Cargando…

High-Dose-Rate Brachytherapy Monotherapy versus Image-Guided Intensity-Modulated Radiotherapy with Helical Tomotherapy for Patients with Localized Prostate Cancer

The aim of this paper is to compare outcomes between high-dose-rate interstitial brachytherapy (HDR-BT) monotherapy and image-guided intensity-modulated radiotherapy (IG-IMRT) for localized prostate cancer. We examined 353 HDR-BT and 270 IG-IMRT patients. To reduce background selection bias, we used...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamazaki, Hideya, Masui, Koji, Suzuki, Gen, Nakamura, Satoaki, Shimizu, Daisuke, Nishikawa, Tatsuyuki, Okabe, Haruumi, Yoshida, Ken, Kotsuma, Tadayuki, Tanaka, Eiichi, Otani, Keisuke, Yoshioka, Yasuo, Ogawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162691/
https://www.ncbi.nlm.nih.gov/pubmed/30201941
http://dx.doi.org/10.3390/cancers10090322
_version_ 1783359197769891840
author Yamazaki, Hideya
Masui, Koji
Suzuki, Gen
Nakamura, Satoaki
Shimizu, Daisuke
Nishikawa, Tatsuyuki
Okabe, Haruumi
Yoshida, Ken
Kotsuma, Tadayuki
Tanaka, Eiichi
Otani, Keisuke
Yoshioka, Yasuo
Ogawa, Kazuhiko
author_facet Yamazaki, Hideya
Masui, Koji
Suzuki, Gen
Nakamura, Satoaki
Shimizu, Daisuke
Nishikawa, Tatsuyuki
Okabe, Haruumi
Yoshida, Ken
Kotsuma, Tadayuki
Tanaka, Eiichi
Otani, Keisuke
Yoshioka, Yasuo
Ogawa, Kazuhiko
author_sort Yamazaki, Hideya
collection PubMed
description The aim of this paper is to compare outcomes between high-dose-rate interstitial brachytherapy (HDR-BT) monotherapy and image-guided intensity-modulated radiotherapy (IG-IMRT) for localized prostate cancer. We examined 353 HDR-BT and 270 IG-IMRT patients. To reduce background selection bias, we used the method of inverse probability treatment weighting (IPTW) with propensity scores. The actuarial five-year biochemical failure-free survival rates were 92.9% and 96.7% (p = 0.1847; p = 0.077 in IPTW) for HDR-BT and IG-IMRT, respectively; they were 100% and 95.8% (p = 0.286) for the low-risk group, 95.6% and 92% (p = 0.42) for the intermediate-risk group, 90.4% and 84.9% (p = 0.1059; p = 0.04 in IPTW) for the high-risk group, and 87.1% and 89.2% (p = 0.3816) for the very-high-risk group. In the assessment of accumulated incidences of grade ≥ 2 toxicity (Common Terminology Criteria for Adverse Events version 4.0) at five years, HDR-BT monotherapy showed higher genitourinary toxicity (11.9%) than IG-IMRT (3.3%) (p < 0.0001). The gastrointestinal toxicity was equivalent for HDR-BT (2.3%) and IG-IMRT (5.5%) (p = 0.063). No Grade 4 or 5 toxicity was detected in either modality. HDR-BT showed higher genitourinary toxicity than IG-IMRT. HDR-BT and IG-IMRT showed equivalent outcomes in low-, intermediate-, and very-high-risk groups. For high-risk patients, HDR-BT showed potential to improve prostate-specific antigen (PSA) control rate compared to IG-IMRT.
format Online
Article
Text
id pubmed-6162691
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-61626912018-10-02 High-Dose-Rate Brachytherapy Monotherapy versus Image-Guided Intensity-Modulated Radiotherapy with Helical Tomotherapy for Patients with Localized Prostate Cancer Yamazaki, Hideya Masui, Koji Suzuki, Gen Nakamura, Satoaki Shimizu, Daisuke Nishikawa, Tatsuyuki Okabe, Haruumi Yoshida, Ken Kotsuma, Tadayuki Tanaka, Eiichi Otani, Keisuke Yoshioka, Yasuo Ogawa, Kazuhiko Cancers (Basel) Article The aim of this paper is to compare outcomes between high-dose-rate interstitial brachytherapy (HDR-BT) monotherapy and image-guided intensity-modulated radiotherapy (IG-IMRT) for localized prostate cancer. We examined 353 HDR-BT and 270 IG-IMRT patients. To reduce background selection bias, we used the method of inverse probability treatment weighting (IPTW) with propensity scores. The actuarial five-year biochemical failure-free survival rates were 92.9% and 96.7% (p = 0.1847; p = 0.077 in IPTW) for HDR-BT and IG-IMRT, respectively; they were 100% and 95.8% (p = 0.286) for the low-risk group, 95.6% and 92% (p = 0.42) for the intermediate-risk group, 90.4% and 84.9% (p = 0.1059; p = 0.04 in IPTW) for the high-risk group, and 87.1% and 89.2% (p = 0.3816) for the very-high-risk group. In the assessment of accumulated incidences of grade ≥ 2 toxicity (Common Terminology Criteria for Adverse Events version 4.0) at five years, HDR-BT monotherapy showed higher genitourinary toxicity (11.9%) than IG-IMRT (3.3%) (p < 0.0001). The gastrointestinal toxicity was equivalent for HDR-BT (2.3%) and IG-IMRT (5.5%) (p = 0.063). No Grade 4 or 5 toxicity was detected in either modality. HDR-BT showed higher genitourinary toxicity than IG-IMRT. HDR-BT and IG-IMRT showed equivalent outcomes in low-, intermediate-, and very-high-risk groups. For high-risk patients, HDR-BT showed potential to improve prostate-specific antigen (PSA) control rate compared to IG-IMRT. MDPI 2018-09-10 /pmc/articles/PMC6162691/ /pubmed/30201941 http://dx.doi.org/10.3390/cancers10090322 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yamazaki, Hideya
Masui, Koji
Suzuki, Gen
Nakamura, Satoaki
Shimizu, Daisuke
Nishikawa, Tatsuyuki
Okabe, Haruumi
Yoshida, Ken
Kotsuma, Tadayuki
Tanaka, Eiichi
Otani, Keisuke
Yoshioka, Yasuo
Ogawa, Kazuhiko
High-Dose-Rate Brachytherapy Monotherapy versus Image-Guided Intensity-Modulated Radiotherapy with Helical Tomotherapy for Patients with Localized Prostate Cancer
title High-Dose-Rate Brachytherapy Monotherapy versus Image-Guided Intensity-Modulated Radiotherapy with Helical Tomotherapy for Patients with Localized Prostate Cancer
title_full High-Dose-Rate Brachytherapy Monotherapy versus Image-Guided Intensity-Modulated Radiotherapy with Helical Tomotherapy for Patients with Localized Prostate Cancer
title_fullStr High-Dose-Rate Brachytherapy Monotherapy versus Image-Guided Intensity-Modulated Radiotherapy with Helical Tomotherapy for Patients with Localized Prostate Cancer
title_full_unstemmed High-Dose-Rate Brachytherapy Monotherapy versus Image-Guided Intensity-Modulated Radiotherapy with Helical Tomotherapy for Patients with Localized Prostate Cancer
title_short High-Dose-Rate Brachytherapy Monotherapy versus Image-Guided Intensity-Modulated Radiotherapy with Helical Tomotherapy for Patients with Localized Prostate Cancer
title_sort high-dose-rate brachytherapy monotherapy versus image-guided intensity-modulated radiotherapy with helical tomotherapy for patients with localized prostate cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162691/
https://www.ncbi.nlm.nih.gov/pubmed/30201941
http://dx.doi.org/10.3390/cancers10090322
work_keys_str_mv AT yamazakihideya highdoseratebrachytherapymonotherapyversusimageguidedintensitymodulatedradiotherapywithhelicaltomotherapyforpatientswithlocalizedprostatecancer
AT masuikoji highdoseratebrachytherapymonotherapyversusimageguidedintensitymodulatedradiotherapywithhelicaltomotherapyforpatientswithlocalizedprostatecancer
AT suzukigen highdoseratebrachytherapymonotherapyversusimageguidedintensitymodulatedradiotherapywithhelicaltomotherapyforpatientswithlocalizedprostatecancer
AT nakamurasatoaki highdoseratebrachytherapymonotherapyversusimageguidedintensitymodulatedradiotherapywithhelicaltomotherapyforpatientswithlocalizedprostatecancer
AT shimizudaisuke highdoseratebrachytherapymonotherapyversusimageguidedintensitymodulatedradiotherapywithhelicaltomotherapyforpatientswithlocalizedprostatecancer
AT nishikawatatsuyuki highdoseratebrachytherapymonotherapyversusimageguidedintensitymodulatedradiotherapywithhelicaltomotherapyforpatientswithlocalizedprostatecancer
AT okabeharuumi highdoseratebrachytherapymonotherapyversusimageguidedintensitymodulatedradiotherapywithhelicaltomotherapyforpatientswithlocalizedprostatecancer
AT yoshidaken highdoseratebrachytherapymonotherapyversusimageguidedintensitymodulatedradiotherapywithhelicaltomotherapyforpatientswithlocalizedprostatecancer
AT kotsumatadayuki highdoseratebrachytherapymonotherapyversusimageguidedintensitymodulatedradiotherapywithhelicaltomotherapyforpatientswithlocalizedprostatecancer
AT tanakaeiichi highdoseratebrachytherapymonotherapyversusimageguidedintensitymodulatedradiotherapywithhelicaltomotherapyforpatientswithlocalizedprostatecancer
AT otanikeisuke highdoseratebrachytherapymonotherapyversusimageguidedintensitymodulatedradiotherapywithhelicaltomotherapyforpatientswithlocalizedprostatecancer
AT yoshiokayasuo highdoseratebrachytherapymonotherapyversusimageguidedintensitymodulatedradiotherapywithhelicaltomotherapyforpatientswithlocalizedprostatecancer
AT ogawakazuhiko highdoseratebrachytherapymonotherapyversusimageguidedintensitymodulatedradiotherapywithhelicaltomotherapyforpatientswithlocalizedprostatecancer